esketamine

GPTKB entity

Statements (51)
Predicate Object
gptkbp:instanceOf gptkb:chemical_compound
gptkb:drug
gptkbp:abusePotential moderate
gptkbp:administeredBy nasal spray
gptkbp:approvedBy gptkb:European_Union
gptkb:United_States
gptkb:FDA
gptkbp:ATCCode gptkb:N06AX27
gptkbp:brand gptkb:Spravato
gptkbp:CASNumber gptkb:33643-46-8
gptkbp:chirality S-(+)-enantiomer
gptkbp:contraindication intracerebral hemorrhage
aneurysmal vascular disease
hypersensitivity to esketamine
gptkbp:controlledSubstanceSchedule gptkb:Schedule_III_(US)
gptkbp:discoveredBy gptkb:Calvin_Stevens
gptkbp:drugClass dissociative anesthetic
antidepressant
gptkbp:eliminationHalfLife 7-12 hours
gptkbp:firstSynthesized 1962
gptkbp:hasBoxedWarning sedation
abuse and misuse
suicidal thoughts and behaviors
gptkbp:hasEnantiomer gptkb:arketamine
gptkbp:hasMolecularFormula C13H16ClNO
https://www.w3.org/2000/01/rdf-schema#label esketamine
gptkbp:isomerOf gptkb:ketamine
gptkbp:IUPACName (S)-2-(2-chlorophenyl)-2-(methylamino)cyclohexanone
gptkbp:legalStatus prescription only
gptkbp:mechanismOfAction NMDA receptor antagonist
glutamatergic modulator
gptkbp:metabolism liver
gptkbp:molecularWeight 237.7 g/mol
gptkbp:pregnancyCategory not recommended
gptkbp:PubChem_CID 123590
gptkbp:relatedTo gptkb:memantine
gptkb:dextromethorphan
gptkb:phencyclidine
gptkbp:routeOfAdministration intravenous
intranasal
gptkbp:sideEffect nausea
dizziness
dissociation
sedation
increased blood pressure
gptkbp:smiles CN[C@@H](C1CCCCC1=O)C2=CC=CC=C2Cl
gptkbp:UNII T9P6G9F5MQ
gptkbp:usedFor gptkb:major_depressive_disorder
treatment-resistant depression
gptkbp:bfsParent gptkb:ketamine
gptkbp:bfsLayer 6